Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:48 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:48 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Study Favors Masimo's (MASI) SedLine for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.
Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable
by Zacks Equity Research
Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.
Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings
by Zacks Equity Research
The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Masimo (MASI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study
by Zacks Equity Research
Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.
Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI
by Zacks Equity Research
Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.
Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse
by Zacks Equity Research
Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.
Masimo (MASI) Strengthens Global Footprint With New Launch
by Zacks Equity Research
Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.
Masimo (MASI) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study
by Zacks Equity Research
Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.
Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study
by Zacks Equity Research
Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.
Here's Why Momentum in Masimo (MASI) Should Keep going
by Zacks Equity Research
Masimo (MASI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.
Masimo (MASI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.